A phase III,randomized, double-blind, active comparator-controlled long-term safety and tolerability study of SEP-363856 in adults with schizophrenia

At a glance
Trial Overview
Trial Details
Interventions
Trial History
References

Trial Profile

A phase III,randomized, double-blind, active comparator-controlled long-term safety and tolerability study of SEP-363856 in adults with schizophrenia

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ulotaront (Primary)
Indications Schizophrenia
Focus Adverse reactions
Acronyms DIAMOND 4

Most Recent Events

01 Oct 2019 New trial record
27 Sep 2019 According to a Sunovion Pharmaceuticals media release, the company announced that along with PsychoGenics Inc, the DIAMOND (Developing Innovative Approaches for Mental Disorders) Phase 3 studies for SEP-363856 has been initiated.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com